Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life

Journal of Biological Chemistry

Volumn 287, Issue 27, 2012, Pages 22927-22937

  Andersen, Jan Terje ^a,b   Foss, Stian ^a,b   Kenanova, Vania E ^c,e   Olafsen, Tove ^c,f   Leikfoss, Ingvild S ^a,b,g   Roopenian, Derry C ^d   Wu, Anna M ^c   Sandlie, Inger ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JACKSON LABORATORY   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f ImaginAb Inc   (United States)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ABILITIES; CARCINOEMBRYONIC ANTIGEN; CROSS-SPECIES; IGG-FC REGION; IN-VITRO; IN-VITRO ASSAYS; IN-VIVO; NEONATAL FC RECEPTORS; TRANSGENIC MICE; VARIABLE FRAGMENT;

ANTIBODIES; ANTIGENS; BLOOD; MACROPHAGES; PLANTS (BOTANY);

MAMMALS;

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CHIMERA; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENETIC ENGINEERING; HALF LIFE TIME; IN VITRO STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODY SPECIFICITY; CARCINOEMBRYONIC ANTIGEN; CROSS REACTIONS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTEIN ENGINEERING; RECEPTORS, FC; RECEPTORS, IGG; SINGLE-CHAIN ANTIBODIES; SPECIES SPECIFICITY;

MUS; MUS MUSCULUS;

EID: 84863304928     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.355131     Document Type: Article

References (57)

1. Holliger, P., and Hudson, P. J. (2005) Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136 (Pubitemid 41486394)
2. Kenanova, V., and Wu, A. M. (2006) Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv. 3, 53-70 (Pubitemid 43056391)
3. Wu, A. M., and Senter, P. D. (2005) Arming antibodies. Prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (Pubitemid 41486395)
4. Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., and Ward, E. S. (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15, 637-640 (Pubitemid 27291163)
5. Kamei, D. T., Lao, B. J., Ricci, M. S., Deshpande, R., Xu, H., Tidor, B., and Lauffenburger, D. A. (2005) Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol. Bioeng. 92, 748-760 (Pubitemid 41772470)
6. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S., Avanessian, L., Choi, E. Y., Shaffer, D. J., Eden, P. A., and Anderson, C. L. (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fccoupled drugs. J. Immunol. 170, 3528-3533 (Pubitemid 36359219)
7. Akilesh, S., Huber, T. B., Wu, H., Wang, G., Hartleben, B., Kopp, J. B., Miner, J. H., Roopenian, D. C., Unanue, E. R., and Shaw, A. S. (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl. Acad. Sci. U.S.A. 105, 967-972 (Pubitemid 351282065)
8. Blumberg, R. S., Koss, T., Story, C. M., Barisani, D., Polischuk, J., Lipin, A., Pablo, L., Green, R., and Simister, N. E. (1995) A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J. Clin. Invest. 95, 2397-2402
9. Akilesh, S., Christianson, G. J., Roopenian, D. C., and Shaw, A. S. (2007) Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J. Immunol. 179, 4580-4588
10. Zhu, X., Meng, G., Dickinson, B. L., Li, X., Mizoguchi, E., Miao, L., Wang, Y., Robert, C., Wu, B., Smith, P. D., Lencer, W. I., and Blumberg, R. S. (2001) MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J. Immunol. 166, 3266-3276 (Pubitemid 33117326)
11. Qiao, S. W., Kobayashi, K., Johansen, F. E., Sollid, L. M., Andersen, J. T., Milford, E., Roopenian, D. C., Lencer, W. I., and Blumberg, R. S. (2008) Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. U.S.A. 105, 9337-9342
12. + dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 108, 9927-9932
13. Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., and Ward, E. S. (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. U.S.A. 106, 2788-2793
14. Ward, E. S., Zhou, J., Ghetie, V., and Ober, R. J. (2003) Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol. 15, 187-195 (Pubitemid 36267110)
15. Ober, R. J., Martinez, C., Lai, X., Zhou, J., and Ward, E. S. (2004) Exocytosis of IgG as mediated by the receptor, FcRn. An analysis at the single-molecule level. Proc. Natl. Acad. Sci. U.S.A. 101, 11076-11081 (Pubitemid 38989586)
16. Prabhat, P., Gan, Z., Chao, J., Ram, S., Vaccaro, C., Gibbons, S., Ober, R. J., and Ward, E. S. (2007) Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc. Natl. Acad. Sci. U.S.A. 104, 5889-5894 (Pubitemid 47175629)
17. Kim, J. K., Firan, M., Radu, C. G., Kim, C. H., Ghetie, V., and Ward, E. S. (1999) Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29, 2819-2825 (Pubitemid 30099006)
18. Medesan, C., Matesoi, D., Radu, C., Ghetie, V., and Ward, E. S. (1997) Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol. 158, 2211-2217 (Pubitemid 127470004)
19. Raghavan, M., Chen, M. Y., Gastinel, L. N., and Bjorkman, P. J. (1994) Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1, 303-315
20. Ober, R. J., Radu, C. G., Ghetie, V., and Ward, E. S. (2001) Differences in promiscuity for antibody-FcRn interactions across species. Implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559 (Pubitemid 33133882)
21. Zhou, J., Mateos, F., Ober, R. J., and Ward, E. S. (2005) Conferring the binding properties of the mouseMHCclass I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J. Mol. Biol. 345, 1071-1081 (Pubitemid 40092225)
22. Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E., and Sandlie, I. (2010) Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285, 4826-4836
23. Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., and Tsurushita, N. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213-6216 (Pubitemid 38248752)
24. Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., and Tsurushita, N. (2006) An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176, 346-356 (Pubitemid 43023280)
25. Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., and Roopenian, D. C. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model. Potential application in humorally mediated autoimmune disease. Int. Immunol. 18, 1759-1769 (Pubitemid 44884038)
26. Dall'Acqua, W. F., Kiener, P. A., and Wu, H. (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514-23524 (Pubitemid 44274126)
27. Blumberg, R. S., and Lencer, W. I. (2005) Antibodies in the breakdown lane. Nat. Biotechnol. 23, 1232-1234
28. Vaccaro, C., Zhou, J., Ober, R. J., and Ward, E. S. (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283-1288 (Pubitemid 41486856)
29. Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J., and Ward, E. S. (2006) Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl. Acad. Sci. U.S.A. 103, 18709-18714 (Pubitemid 44913475)
30. Wu, A. M., Yazaki, P. J., Tsai, S., Nguyen, K., Anderson, A. L., McCarthy, D. W., Welch, M. J., Shively, J. E., Williams, L. E., Raubitschek, A. A., Wong, J. Y., Toyokuni, T., Phelps, M. E., and Gambhir, S. S. (2000) High resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. U.S.A. 97, 8495-8500 (Pubitemid 30639701)
31. 124I-Labeled engineered anti-CEA minibodies and diabodies allow high contrast, antigen-specific small animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44, 1962-1969
32. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin. Cancer Res. 10, 5014-5021
33. Hu, S., Shively, L., Raubitschek, A., Sherman, M., Williams, L. E., Wong, J. Y., Shively, J. E., and Wu, A. M. (1996) Minibody. A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) that exhibits rapid, high level targeting of xenografts. Cancer Res. 56, 3055-3061
34. Boucher, D., Cournoyer, D., Stanners, C. P., and Fuks, A. (1989) Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res. 49, 847-852 (Pubitemid 19064334)
35. Esteban, J. M., Paxton, R., Mehta, P., Battifora, H., and Shively, J. E. (1993) Sensitivity and specificity of Gold types 1-5 anti-carcinoembryonic antigen monoclonal antibodies. Immunohistologic characterization in colorectal cancer and normal tissues. Hum. Pathol. 24, 322-328 (Pubitemid 23086369)
36. Kenanova, V., Olafsen, T., Crow, D. M., Sundaresan, G., Subbarayan, M., Carter, N. H., Ikle, D. N., Yazaki, P. J., Chatziioannou, A. F., Gambhir, S. S., Williams, L. E., Shively, J. E., Colcher, D., Raubitschek, A. A., and Wu, A. M. (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen singlechain Fv-Fc antibody fragments. Cancer Res. 65, 622-631
37. Kenanova, V., Olafsen, T., Williams, L. E., Ruel, N. H., Longmate, J., Yazaki, P. J., Shively, J. E., Colcher, D., Raubitschek, A. A., and Wu, A. M. (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Optimal pharmacokinetics for therapy. Cancer Res. 67, 718-726 (Pubitemid 46192212)
38. Andersen, J. T., Justesen, S., Fleckenstein, B., Michaelsen, T. E., Berntzen, G., Kenanova, V. E., Daba, M. B., Lauvrak, V., Buus, S., and Sandlie, I. (2008) Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J. 275, 4097-4110
39. Popov, S., Hubbard, J. G., Kim, J., Ober, B., Ghetie, V., and Ward, E. S. (1996) The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol. Immunol. 33, 521-530 (Pubitemid 26228389)
40. Berntzen, G., Lunde, E., Flobakk, M., Andersen, J. T., Lauvrak, V., and Sandlie, I. (2005) Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J. Immunol. Methods 298, 93-104 (Pubitemid 40545096)
41. Blumberg, D., Hochwald, S., Brennan, M. F., and Burt, M. (1995) Interleukin- 6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism 44, 145-146
42. Stein, C., Kling, L., Proetzel, G., Roopenian, D. C., de Angelis, M. H., Wolf, E., and Rathkolb, B. (2012) Clinical chemistry of human FcRn transgenic mice. Mamm. Genome 23, 259-269
43. Nimmerjahn, F., and Ravetch, J. V. (2008) Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47
44. Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., and Ward, E. S. (2001) The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. Int. Immunol. 13, 993-1002 (Pubitemid 32750502)
45. Bitonti, A. J., Dumont, J. A., Low, S. C., Peters, R. T., Kropp, K. E., Palombella, V. J., Stattel, J. M., Lu, Y., Tan, C. A., Song, J. J., Garcia, A. M., Simister, N. E., Spiekermann, G. M., Lencer, W. I., and Blumberg, R. S. (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in nonhuman primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. U.S.A. 101, 9763-9768 (Pubitemid 38869310)
46. Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., and Lencer, W. I. (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 196, 303-310 (Pubitemid 34875660)
47. Spiegelberg, H. L., Fishkin, B. G., and Grey, H. M. (1968) Catabolism of human γG-immunoglobulins of different heavy chain subclasses. I. Catabolism of γG-myeloma proteins in man. J. Clin. Invest. 47, 2323-2330
48. Morell, A., Terry, W. D., and Waldmann, T. A. (1970) Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49, 673-680
49. Spiegelberg, H. L. (1974) Biological activities of immunoglobulins of different classes and subclasses. Adv. Immunol. 19, 259-294
50. Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., Jonsdottir, I., van der Schoot, C. E., and Vidarsson, G. (2011) Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2, 599
51. Martin, W. L., West, A. P., Jr., Gan, L., and Bjorkman, P. J. (2001) Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex. Mechanism of pH-dependent binding. Mol. Cell 7, 867-877 (Pubitemid 32436446)
52. Girgis, M. D., Olafsen, T., Kenanova, V., McCabe, K. E., Wu, A. M., and Tomlinson, J. S. (2011) Targeting CEA in pancreas cancer xenografts with a mutated scFv-Fc antibody fragment. EJNMMI Res. 1, 24
53. Olafsen, T., Kenanova, V. E., Sundaresan, G., Anderson, A. L., Crow, D., Yazaki, P. J., Li, L., Press, M. F., Gambhir, S. S., Williams, L. E., Wong, J. Y., Raubitschek, A. A., Shively, J. E., and Wu, A. M. (2005) Optimizing radio-labeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65, 5907-5916 (Pubitemid 40911197)
54. Olafsen, T., Sirk, S. J., Betting, D. J., Kenanova, V. E., Bauer, K. B., Ladno, W., Raubitschek, A. A., Timmerman, J. M., and Wu, A. M. (2010) ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng. Des. Sel. 23, 243-249
55. Milenic, D. E., Brady, E. D., and Brechbiel, M. W. (2004) Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov. 3, 488-499
56. Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W., Sproule, T. J., Lazar, G. A., Roopenian, D. C., and Desjarlais, J. R. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157-159
57. Deisenhofer, J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20, 2361-2370